SOUTH SAN FRANCISCO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the first quarter of fiscal year 2025 (FY2025) after the market closes on Thursday, August 8, 2024. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter's ...

The de-identified data from the study will be made available to approved researchers, and access to the scientific database will be available to nonprofit researchers and institutions at no cost. Behind every devastating statistic are people from communities across the U.S. impacted by lung cancer. Through this collaboration, advocacy organizations, lung cancer survivors and advocates, and 23andMe hope ultimately to help advance research toward finding a cure for this disease. "Studying the genetics of lung ...

Core Insights - Lung cancer remains a critical area of unmet need despite advances in treatment options, with the disease being the leading cause of cancer deaths in the U.S. [4][11] - The Lung Cancer Genetics Study aims to enhance research by collecting genetic, clinical, and patient-reported data to improve detection, risk reduction, and care for lung cancer patients [8][11] Company Overview - 23andMe Holding Co. is a genetic health and biopharmaceutical company that collaborates with 20 lung cancer advocacy organizations to conduct the Lung Cancer Genetics Study [4][9] - The study will utilize the 23andMe research platform to gather critical data from participants, which will be made available to approved researchers at no cost [5][12] Study Details - The study aims to recruit 10,000 individuals diagnosed with lung cancer, with no restrictions on cancer type, stage, gender, or smoking status [14] - Participants will receive 23andMe kits at no cost, and the study seeks to reflect the diversity of communities affected by lung cancer [8][14] Research Goals - The study intends to fill a gap in comprehensive databases that connect genetic, clinical, and patient-reported data, ultimately improving treatment and care for lung cancer [8][11] - It is estimated that in 2024, 234,000 new lung cancer cases will be diagnosed in the U.S., highlighting the urgent need for research [11]

SOUTH SAN FRANCISCO, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading preventive health and therapeutics company, and Nightingale Health Plc, a pioneer in biomarker testing and risk prediction, today announced a strategic collaboration to pilot Nightingale Health's clinicallyvalidated and cost-effective blood metabolomics panel with a cohort of 23andMe members. 23andMe currently offers its annual members the option for blood testing and provides interactive tools like He ...

Core Insights - 23andMe and Nightingale Health have announced a strategic collaboration to pilot a blood metabolomics panel with 23andMe members, aiming to enhance preventive health measures and risk prediction [1][5][6] Group 1: Collaboration Details - The pilot will utilize Nightingale's Remote Health Check, which measures various biomarkers from a single blood sample, including cholesterols and fatty acids, to guide lifestyle interventions [2][5] - Up to 5,000 23andMe+ Premium and Total Health members will receive blood testing at no cost, allowing the companies to gather customer feedback on the testing process and data utility [4][5] Group 2: Technological Integration - The collaboration aims to combine the strengths of both companies, enhancing 23andMe's existing health services with Nightingale's advanced biomarker testing technology [6] - This partnership is expected to provide a comprehensive health assessment and continuous tracking of health progress for customers [5][6] Group 3: Company Vision - Both companies share a vision of empowering individuals to identify health risks and prevent diseases through proactive testing and lifestyle changes [5][6] - The collaboration is seen as a significant step in Nightingale Health's strategy to access the consumer health market [6]

Penny stocks are some of the most affordable investments on the market, valued at less than $5. They can hold a unique and intriguing position that can be highly profitable. However, despite their low prices, these stocks are often the riskiest to own. Many are still in the process of establishing themselves in their respective markets or lack a solid foundation for significant growth. That said, there are exceptions. These three penny stocks are loaded with growth potential and have exciting developments c ...

Core Points - The U.K.'s Information Commissioner's Office (ICO) and the Office of the Privacy Commissioner of Canada (OPC) are investigating 23andMe due to a significant data breach that had international implications [1][7] - The breach involved hackers accessing around 14,000 customer accounts, which allowed them to scrape data on approximately 6.9 million users due to an opt-in feature called DNA Relatives [2][3] - The investigation will assess the extent of the exposed information, the adequacy of 23andMe's data protection measures, and whether the company provided sufficient notification to the relevant authorities [4] Data Breach Details - Last year, 23andMe reported a security incident affecting the genetic and ancestry data of 6.9 million users, which is about half of its total user base [3] - The company was unaware of the breach for around five months, from April to September 2023, and only learned of it in October 2023 when the stolen data was advertised online [3] - The compromised data included personal information such as names, birth years, relationship labels, DNA sharing percentages, ancestry reports, and self-reported locations [6] Regulatory Response - The joint investigation by the ICO and OPC aims to ensure that organizations handling sensitive personal information have appropriate security measures in place [8] - ICO Commissioner John Edwards emphasized the need for public trust in organizations managing sensitive data [8]

SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, today released a new genetic Bipolar Disorder report (Powered by 23andMe Research) for 23andMe+ Premium members, informing them if they are at higher likelihood for being diagnosed with the condition. Bipolar disorder is a mental health condition that can cause extreme and unusual shifts in mood, energy, behavior and activity, ranging from highs (mania) to ...

Is altruism a good idea for an unprofitable capitalistic enterprise? Genetic database builder 23andMe (ME -11.45%) stock slid 10% through 12:05 p.m. ET Tuesday. Curiously, though, the news that 23andMe reported today seemed generally of the "good" variety. The company announced a collaboration with the nonprofit Colorectal Cancer Alliance "to help advance research on colorectal cancer in the Black/African American community." Now, why might investors consider this bad news for 23andMe stock? Non-profit plus ...

Core Insights - 23andMe and the Colorectal Cancer Alliance are collaborating on a study to advance research on colorectal cancer specifically within the Black/African American community [1][4] - The study aims to recruit individuals of African ancestry diagnosed with colorectal cancer to address the significant health disparities faced by this demographic [1][5] Group 1: Colorectal Cancer Impact - Colorectal cancer is the third most common cancer among Black men and women, with Black Americans experiencing a 15% higher likelihood of developing the disease and a 35% higher mortality rate compared to non-Hispanic white Americans [2] - There is an increasing trend of early onset colorectal cancer in the Black community, highlighting the need for increased awareness and early detection resources [2] Group 2: Research Gap and Study Objectives - 23andMe has identified a gap in research regarding colorectal cancer in the Black community, which the new study aims to fill by improving polygenic scores and informing individuals about genetic risks [3][4] - The study will focus on individuals aged 18 and older who have been diagnosed with colorectal cancer, aiming to enhance understanding of genetic factors affecting this population [5] Group 3: Collaboration Goals - The collaboration seeks to educate the Black community on the importance of family history and risk factors for colorectal cancer, promoting early detection and prevention strategies [4] - 23andMe's research will utilize its database of genetic and health information to develop insights that can lead to better health outcomes for the Black community [3][4]